Vitamin D for Shortness of Breath

Vitamin D helps only where deficiency exists. In severely deficient COPD and asthma patients, repletion cuts exacerbation rates; in replete patients it does nothing.

Overview

Vitamin D helps only where deficiency exists. In severely deficient COPD and asthma patients, repletion cuts exacerbation rates; in replete patients it does nothing.

Verdict

Mixed evidence

Reduces exacerbations in COPD and asthma patients who are actually deficient. No benefit in people with adequate vitamin D status.

How It Works

Vitamin D modulates innate immunity through cathelicidin induction and dampens airway inflammation. Deficiency is associated with more frequent respiratory infection, which drives most exacerbations of obstructive lung disease.

Dosing & Protocol

Typical dose

Recommended dose: 1,000-2,000 IU daily, or correction of documented deficiency
Expected timeframe: Repletion takes 8-12 weeks; exacerbation benefit is measured over a year.

Protocol

form: Vitamin D3 (cholecalciferol), taken daily rather than as bolus doses
duration: 6-12 months, counting exacerbations rather than judging day-to-day breathing
co factor: Take with the largest meal and continue all inhalers. Evidence is mixed and indirect: breathlessness itself has not been a trial outcome. What exists is meta-analysis evidence that vitamin D supplementation reduces asthma exacerbation rates, and similar signals in COPD, in both cases confined to people who were vitamin D deficient at baseline. Severe deficiency also causes proximal muscle weakness, including respiratory muscles.
titration: Target 75-125 nmol/L; asthma and COPD trials used daily or weekly dosing under supervision
starting dose: 1000-2000 IU (25-50 mcg) vitamin D3 daily with a fat-containing meal, after checking 25-hydroxyvitamin D

Evidence

What the studies say

A 2019 individual participant data meta-analysis of COPD trials (Jolliffe, Thorax) found vitamin D supplementation reduced moderate-to-severe exacerbation rates by around 45% in participants with baseline 25(OH)D below 25 nmol/L, with no effect in those with higher levels. The parallel asthma IPD meta-analysis showed a similar pattern for severe exacerbations. The large VITAL trial in unselected adults found no respiratory benefit, consistent with the deficiency-dependent effect. No trial has shown improvement in lung function or in breathlessness itself.

Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data

Score: 8/10

2019

meta_analysis

n=469

Jolliffe DA, Greenberg L, Hooper RL

Vitamin D reduced moderate-to-severe exacerbation rates in participants with baseline 25(OH)D below 25 nmol/L.

View source

Safety

Caveats

Test 25(OH)D rather than supplementing blindly. High intermittent bolus dosing has performed worse than daily dosing in respiratory trials. Doses above 4,000 IU daily need monitoring.

Less likely to help if

Anyone with a 25(OH)D level already above 50 nmol/L, and anyone expecting improvement in lung function or day-to-day breathlessness.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.